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468Objectives: The aim of the present study was to identify the predictors of 5-year survival in elderly patients un-
dergoing orthotopic heart transplantation (OHT).
Methods:A review of the United Network for Organ Sharing database was conducted of recipients 60 years old
or older undergoing OHT from 1995 to 2004. The variables were compared between the 5-year survivors and the
patients who died within 5 years of OHT. A multivariate logistic regression model was constructed using the
covariates significantly associated with 5-year survival on univariate analysis.
Results: A total of 5330 elderly patients underwent OHT during the study period. Of these patients, 3492
(65.5%) were 5-year survivors, 1580 (29.6%) had died within 5 years of OHT and were considered controls,
and 258 (4.8%) were lost to follow-up. The predictors of improved 5-year survival included younger age
(odds ratio [OR], 0.97; 95% confidence interval [CI], 0.95–1.00; P ¼ .03), lower creatinine (OR, 0.92; 95%
CI, 0.87–0.98; P ¼ .01), white race (OR, 1.23; 95% CI, 1.02–1.49; P ¼ .03), shorter ischemic time (OR,
0.93; 95% CI, 0.87–0.99; P ¼ .02), and younger donor age (OR, 0.99; 95% CI, 0.99–1.00; P ¼ .03). The
following significantly reduced the odds of surviving to 5 years: mechanical ventilation (OR, 0.48; 95% CI,
0.33–0.71; P<.001), hypertension (OR, 0.79; 95% CI, 0.69–0.91; P ¼ .001), and diabetes (OR, 0.79; 95%
CI, 0.67–0.92; P ¼ .003). Ventricular assist device data were only available for 2538 patients (49.6%).
When added to the multivariate model, the use of a ventricular assist device significantly reduced the odds of
surviving 5 years after OHT (OR, 0.63; 95% CI, 0.50–0.81; P<.001).
Conclusions: In the present study of more than 5000 elderly OHT patients, younger recipient age, white race,
lower creatinine, younger donor age, and shorter ischemic time were associated with improved 5-year survival.
In contrast, bridging with a ventricular assist device, mechanical ventilation, hypertension, and diabetes signif-
icantly decreased the odds of 5-year survival. These findings might be useful for prognostication in this higher
risk patient population. (J Thorac Cardiovasc Surg 2012;143:468-74)The United States Census Bureau has projected that the pro-
portion of the population that is elderly will increase in
coming years, with the number of those aged 65 years or
older doubling in the next 2 decades.1 This will undoubtedly
lead to a greater number of older patients presenting to car-
diac surgeons. It is therefore imperative that the outcomes in
this patient population be studied further in an effort to op-
timize the therapeutic results.
In the realm of heart transplantation, the effect of advanc-
ing age on outcomes is especially important, secondary to
the lack of donor organs and the need to rationally allocate
these limited resources. Initially performed only in patients
younger than 50 years old, orthotopic heart transplantatione Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Med-
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The Journal of Thoracic and Cardiovascular Surg(OHT) is being increasingly performed in older patients de-
spite the conflicting data. Some centers view advanced age
as a contraindication to transplantation, citing data demon-
strating poorer graft and patient survival in the elderly.2,3
Other groups have found equivalent survival in older and
younger recipients.4,5 Regardless, it is clear that careful
preoperative selection of candidates is essential for
acceptable survival. Although transplant outcomes
stratified by age have been studied quite extensively, the
predictors of survival in older OHT recipients are yet to
be determined. The aim of the present study was to
identify the factors predictive of 5-year survival in OHT re-
cipients aged 60 years or older.MATERIALS AND METHODS
Data Source
The source of data for the present study was the Standard Transplant
Analysis and Research files from the United Network for Organ Sharing
(UNOS). This database provides de-identified patient-level data; thus, the
present study was granted exempt status by our institutional review board.
Study Design
The analysis was limited to patients aged 60 years or older undergoing
OHT from 1995 to 2004. Those undergoing retransplantation orery c February 2012
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Kilic et al Cardiothoracic Transplantationmultivisceral transplant were excluded. The control cohort consisted of pa-
tients who died within 5 years of OHT. The data were compared between
these patients and those surviving at least 5 years after OHT. The patients
who were lost to follow-up (alive, but with<5 years of follow-up) were
excluded.
Variables
A total of 32 recipient, donor, hemodynamic, and transplant variables
were compared between the controls and survivors. Univariate analysis
was conducted using the t test for continuous variables and the
chi-square test for categorical variables. Multivariate logistic regression
analysis was performed, incorporating significant predictors on univariate
analysis, with the odds ratios (ORs) and 95% confidence intervals (CIs)
calculated for the covariates. Variables that had more than 15% missing
data were excluded from entry into the multivariate model. P<.05 was
considered significant on both univariate and multivariate analyses. These
analyses were performed using STATA, version 11, software (StataCorp,
College Station, Tex).T
XRESULTS
Study Population
A total of 18,455 adult (18 years) patients underwent
first-time, single-organ OHT during the study period in
the UNOS database. Of these, 5330 (28.9%) were recipi-
ents 60 years old or older. In the present elderly cohort,
1580 patients (29.6%) had died within 5 years of OHT
and were included in the control group and 3492 patients
(65.5%) had survived at least 5 years. The remaining 258
patients (4.8%) were lost to follow-up (alive but with<5
years of follow-up) and were thus excluded.
The patients included in the present analysis had a mean
age of 63.7  3.0 years. The distribution of patient age by
5-year category was as follows: 60 to 64.9 years
(n ¼ 3302; 65.1%), 65 to 69.9 years (n ¼ 1564; 30.8%),
and 70 years or older (n ¼ 206; 4.1%). Most patients
were males (n¼ 4224; 83.3%). The mean body mass index
was 25.5  4.2 kg/m2, and 4385 (86.5%) were white.Baseline Characteristics
A comparison of the baseline characteristics demon-
strated that the 5-year survivors were significantly younger
than the control group (Table 1). The survivors also had
a lower serum creatinine than the controls. A greater per-
centage of survivors were white. Fewer survivors required
mechanical ventilation or intra-aortic balloon pump before
transplantation. Fewer survivors had comorbidities such asThe Journal of Thoracic and Cahypertension and diabetes. The ischemic time was also
shorter in the survivor cohort. The hemodynamic data
were similar between the 2 groups. The indications for
transplantation were also similar. The donors for the
5-year survivors were significantly younger. Otherwise, the
demographic variables of the donors were similar between
the 2 groups. Data on ventricular assist device (VAD) therapy
as bridge-to-transplantation data were only available for
2538 patients (49.6%), because this variable was collected
only in the later years of the study period. Fewer survivors
were bridged to OHTwith a VAD than nonsurvivors.
Univariate and Multivariate Analyses
Univariate logistic regression analysis identified several
potential predictors of 5-year survival. The significant pre-
dictors on univariate analysis included younger age, lower
serum creatinine, white race, shorter ischemic time, and
younger donor age (Table 2). Mechanical ventilation,
intra-aortic balloon pump use, diabetes, hypertension, and
VAD therapy significantly decreased the likelihood of
5-year survival on univariate analysis.
Multivariate analysis was conducted incorporating all
these significant univariate predictors, except for VAD ther-
apy, because 50% of the data were missing for that covari-
ate. In the multivariate model, a lower recipient creatinine
and white race were each found to independently improve
the odds of 5-year survival (Table 3). Younger recipient
age within the elderly cohort was also found to improve
the odds of 5-year survival. The recipient factors associated
with a decreased likelihood of survival included mechanical
ventilation before transplantation, hypertension, and diabe-
tes. A significant inverse correlation was found between the
number of these adverse factors (ventilation, hypertension,
diabetes) and the proportion of 5-year survivors, such that
patients who had none of these factors had 72% 5-year sur-
vivors and patients with 2 or all 3 of these factors had 60%
5-year survivors (P<.001; Figure 1). The donor variables
associated with improved 5-year survival included younger
donor age and shorter ischemic time. Patients with a donor
age older than 40 years and ischemic time longer than 4
hours had a 12% absolute reduction in the proportion of
5-year survivors compared with recipients with a donor
age younger than 25 years and an ischemic time shorter
than 2 hours (P<.001; Figure 2). Although VAD therapy
was initially excluded from the multivariate model because
of the high percentage of missing data, when it was added,
VAD therapy was found to significantly and independently
reduce the likelihood of 5-year survival (OR, 0.63; 95% CI,
0.50–0.81; P<.001).
DISCUSSION
The demand for heart transplantation continues to out-
weigh the supply of available organs. Approximately
3000 patients with end-stage heart disease are on the waitrdiovascular Surgery c Volume 143, Number 2 469
TABLE 1. Baseline characteristics
Variable Controls (n ¼ 1580) 5-y survivors (n ¼ 3492) P value
Recipient
Age (y) 63.9  3.1 63.6  2.9 .005*
Male gender 1309/1580 (82.9) 2915/3492 (83.5) .58
White race 1329/1580 (84.1) 3056/3492 (87.5) .001*
Body mass index (kg/m2) 25.6  4.3 25.5  4.2 .18
Transplant in later era (1999–2004) 927/1580 (58.7) 2079/3492 (59.5) .56
Creatinine 1.6  1.3 1.4  1.2 <.001*
Mechanical ventilation before OHT 71/1580 (4.5) 73/3492 (2.1) <.001*
Intra-aortic balloon pump 113/1580 (7.2) 167/3492 (4.8) .001*
Days on wait list 239.3  351.6 243.3  354.4 .71
Hypertension 690/1495 (46.2) 1331/3295 (40.4) <.001*
Diabetes 369/1514 (24.4) 680/3346 (20.3) .001*
Cytomegalovirus positive 549/784 (70.0) 1253/1785 (70.2) .93
Heart failure etiology
Dilated cardiomyopathy 1287/1580 (81.5) 2880/3492 (82.5) .38
Coronary artery disease 217/1580 (13.7) 447/3492 (12.8) .36
Valvular disease 41/1580 (2.6) 96/3492 (2.8) .75
Hypertrophic cardiomyopathy 3/1580 (0.2) 17/3492 (0.5) .12
Congenital heart disease 4/1580 (0.3) 10/3492 (0.3) .84
Bridged with VAD 160/779 (20.5) 262/1759 (14.9) <.001*
Donor
Age (y) 34.1  13.9 32.6  13.5 <.001*
Male gender 1051/1580 (66.5) 2354/3492 (67.4) .53
White race 1184/1580 (74.9) 2652/3492 (75.6) .44
Body mass index (kg/m2) 25.5  5.2 25.7  5.3 .13
Creatinine 1.2  1.5 1.2  1.5 .96
Antihypertensive agents 229/1539 (14.9) 466/3432 (13.6) .22
Diabetes 28/1558 (1.8) 73/3452 (2.1) .46
Cytomegalovirus positive 937/1566 (59.8) 2040/3451 (59.1) .63
Recipient-donor matching
Identical blood type 1365/1580 (86.4) 3035/3492 (86.9) .61
HLA match (2 antigen match) 360/1304 (27.6) 871/2952 (29.5) .21
Cytomegalovirus match 431/781 (55.2) 982/1777 (55.3) .97
Hemodynamic
Mean PAP (mm Hg) 29.7  10.0 29.3  10.5 .26
PVR (dyne $ s/cm5) 2.5  1.8 2.5  2.1 .33
CO (L/min) 4.3  1.4 4.4  1.4 .06
PCWP (mm Hg) 19.8  8.8 19.5  8.9 .28
TPG (mm Hg) 9.9  5.6 9.7  6.0 .45
Transplantation
Biatrial technique 1177/1537 (76.6) 2536/3414 (74.3) .08
Ischemic time (hr) 3.1  1.1 3.0  1.0 .002*
Data presented as mean  standard deviation or number (percentage). OHT, Orthotopic heart transplantation; VAD, ventricular assist device; HLA, human leukocyte antigen;
PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance; CO, cardiac output; PCWP, pulmonary capillary wedge pressure; TPG, transpulmonary pressure gradient.
*Statistically significant.
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Xlist on any given day, with only 2000 undergoing transplan-
tation each year.6 Given this discrepancy and the need to ra-
tionally allocate these limited resources, strict eligibility
criteria have been developed and are continually revised
to ensure acceptable probability of long-term success.
The recipient upper age limit is one such criterion that has
been debated in the surgical community. Some centers view
advanced age as a contraindication to transplantation, citing
several single-institution studies that have demonstrated470 The Journal of Thoracic and Cardiovascular Surgworse short- and long-term survival in older patients.3,4,7,8
These data have been echoed in the findings of multi-
institutional reports, including those using databases from
UNOS, the Registry of the International Society for Heart
and Lung Transplantation, and the Transplant Cardiologists
Research Database, which have all demonstrated an adverse
effect on survival with increasing recipient age.9-11 However,
several studies have shown equivalent survival between older
and younger cohorts.6,12 These latter data, in addition to theery c February 2012
TABLE 2. Univariate logistic regression analysis
Variable
OR of 5-y survival
(95% CI)
P
value
Recipient
Age (increasing) 0.97 (0.95–0.99) .005*
Male gender 1.05 (0.89–1.23) .58
White race 1.32 (1.12–1.57) .001*
Body mass index (increasing) 0.99 (0.98–1.00) .18
Transplant in later era (1999–2004) 1.10 (0.90–1.34) .35
Creatinine (increasing) 0.89 (0.83–0.95) .001*
Mechanical ventilation before OHT 0.45 (0.33–0.63) <.001*
Intra-aortic balloon pump 0.65 (0.51–0.83) .001*
Days on wait list (increasing) 1.00 (1.00–1.00) .71
Hypertension 0.79 (0.70–0.89) <.001*
Diabetes 0.79 (0.69–0.91) .002*
Cytomegalovirus positive 1.01 (0.84–1.21) .93
Heart failure etiology
Dilated cardiomyopathy 1.07 (0.92–1.25) .38
Coronary artery disease 0.92 (0.77–1.10) .36
Valvular disease 1.06 (0.73–1.54) .75
Hypertrophic cardiomyopathy 2.57 (0.75–8.79) .13
Congenital heart disease 1.13 (0.35–3.61) .84
Bridged with VAD 0.68 (0.54–0.84) <.001*
Donor
Age (increasing) 0.99 (0.99–1.00) <.001*
Male gender 1.04 (0.92–1.18) .53
White race 1.06 (0.92–1.21) .44
Body mass index (increasing) 1.01 (1.00–1.02) .13
Creatinine (increasing) 1.00 (0.96–1.04) .96
Antihypertensive agents 0.90 (0.76–1.07) .22
Diabetes 1.18 (0.76–1.83) .46
Cytomegalovirus positive 0.97 (0.86–1.10) .63
Recipient-donor matching
Identical blood type 1.05 (0.88–1.25) .61
HLA match (2 antigen match) 1.10 (0.95–1.27) .21
Cytomegalovirus match 1.00 (0.85–1.19) .97
Hemodynamic
Mean PAP (increasing) 1.00 (0.99–1.00) .26
PVR (increasing) 0.98 (0.95–1.02) .34
CO (increasing) 1.05 (1.00–1.09) .06
PCWP (increasing) 1.00 (0.99–1.00) .28
TPG (increasing) 1.00 (0.98–1.01) .45
Transplantation
Biatrial technique 0.88 (0.77–1.02) .09
Ischemic time (increasing) 0.91 (0.86–0.97) .002*
OR, Odds ratio; CI, confidence interval; OHT, Orthotopic heart transplantation; VAD,
ventricular assist device;HLA, human leukocyte antigen; PAP, pulmonary artery pres-
sure; PVR, pulmonary vascular resistance; CO, cardiac output; PCWP, pulmonary
capillary wedge pressure; TPG, transpulmonary pressure gradient. *Statistically sig-
nificant.
TABLE 3. Multivariate logistic regression analysis
Variable
OR for 5-y survival
(95% CI)
P
value
Recipient
Age (increasing) 0.98 (0.95–1.00) .03*
White race 1.23 (1.02–1.49) .03*
Creatinine (increasing) 0.92 (0.87–0.98) .01*
Mechanically Ventilated 0.48 (0.33–0.71) <.001*
Intra-aortic balloon pump 0.79 (0.59–1.06) .12
Hypertension 0.79 (0.69–0.91) .001*
Diabetes 0.79 (0.67–0.92) .003*
Donor
Age (increasing) 0.99 (0.99–1.00) .03*
Transplantation
Ischemic time (increasing) 0.93 (0.87–0.99) .02*
Bridging with VADs was excluded frommultivariate analysis because of the high per-
centage of missing data for that covariate. OR, Odds ratio; CI, confidence interval;
VAD, ventricular assist device. *Statistically significant.
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Xidea that the chronologic age might not be a reflection of the
physiologic age, have led some centers to advocate
transplantation in elderly recipients. Regardless, it is clear
that careful selection of candidates is necessary to ensure
acceptable outcomes in older patients.
To appropriately select older candidates for transplanta-
tion, an understanding of the factors associated withThe Journal of Thoracic and Casurvival in this cohort is necessary. The aim of the present
study was to evaluate 32 recipient, donor, hemodynamic,
and recipient-donor matching variables in a large multi-
institutional database for the purpose of identifying those
associated with 5-year survival. A principal finding was
that younger recipient age, white race, and lower creatinine
levels were associated with improved 5-year survival. The
donor factors leading to improved 5-year survival included
younger donor age and shorter ischemic time. In addition,
mechanical ventilation, hypertension, and diabetes in the
recipient significantly reduced the odds of surviving to 5
years after transplantation.
Recipient Age
The finding that younger age within the elderly cohort is
associated with improved survival confirms previous data
that increasing age as a continuous variable is associated
with decreasing survival. The key issue has been finding
an appropriate age cutoff for transplantation, which has
proved difficult, because previous studies have used differ-
ent cutoffs for their data analyses, impeding comparisons.
As mentioned previously, however, selecting a strict cutoff
might not be necessary, because viewing the patients with
regard to their comorbidities and overall health, in addition
to their chronologic age, might be more prudent in predict-
ing the outcomes. That recipient age was an independent
predictor of survival might also reflect a shorter life expec-
tancy, in addition to the increasing comorbidities that ac-
company advancing age.
White Race
Emerging evidence has suggested that race might have
a significant effect on the outcomes of thoracic organ trans-
plantation. In an analysis of more than 20,000 adult OHT re-
cipients, black Americans were found to have significantlyrdiovascular Surgery c Volume 143, Number 2 471
FIGURE 1. Proportion of 5-year survivors by number of adverse risk fac-
tors (mechanical ventilation, hypertension, diabetes). FIGURE 2. Proportion of 5-year survivors by donor age and ischemic
time cohorts.
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Xworse survival than other races.13 In the present study, white
race increased the odds of 5-year survival by 23% in elderly
OHT patients. Whether these survival discrepancies are at-
tributable to biologic differences or socioeconomic issues
such as access to care, or both, remains to be elucidated.
Serum Creatinine
In addition to younger recipient age and white race,
a lower serum creatinine was associated with improved
5-year survival. Renal function is known to decline with
age, and elderly patients are particularly susceptible to
chronic kidney disease and end-stage renal failure.14 In
a single-institution study, the risk of postoperative renal
failure was significantly greater in elderly recipients and
was a primary reason for worse long-term survival com-
pared with younger patients.15 The results from our study
suggest that those elderly patients with relatively greater
impaired renal function preoperatively might be at an espe-
cially greater risk of adverse outcomes and/or earlier death
after transplant. Therefore, it appears that in elderly patients
who are more prone to renal failure, the optimization of re-
nal function before transplantation and close attention to
preserving this function in the postoperative period might
be prudent to achieving acceptable outcomes in this patient
population.
Donor Age and Ischemic Time
With regard to the donor variables, the significant predic-
tors of 5-year survival included younger donor age and
shorter ischemic time. Substantial previous data have
been published on the effect of donor age on outcomes after
OHT. In a report of all adult heart transplantations in the In-
ternational Society for Heart and Lung Transplantation reg-
istry, increasing donor age as a continuous variable was
a significant predictor of 1-, 5-, and 10-year mortality.10
This effect of donor age on outcomes is thought to be in
part a result of an increased risk of transplant coronary ar-
tery disease with older donors and its associated increase
in post-transplant morbidity and mortality.16 In our study,472 The Journal of Thoracic and Cardiovascular Surgthe elderly population was not spared from the adverse ef-
fect of increasing donor age. Although the outcomes in
the elderly might be adversely affected with increasing do-
nor age, it is important to note that expanding the donor pool
by including marginal donors does increase the organ re-
covery rates by 20% to 30% annually, thereby helping to
address the critical shortage of available organs for
OHT.17 With regard to the ischemic time, an analysis of
the UNOS database demonstrated that the adverse effect
of an increasing ischemic time on survival after transplanta-
tion is dependent on donor age.18 Moreover, older donor
hearts were found to be particularly susceptible to the ad-
verse effects of prolonged ischemic times, and younger do-
nor hearts were better able to tolerate prolonged ischemia.
These findings were echoed in our analysis of the elderly
population.
Hypertension
The factors that significantly decreased the odds of
surviving to 5 years after transplantation included hyperten-
sion, diabetes, andmechanical ventilation. As demonstrated
in Figure 1, a 12% absolute reduction was found in the pro-
portion of 5-year survivors for those patients with 2 or more
of these factors compared with thosewith none of them. The
observation that hypertension reduced survival might be be-
cause it is an established risk factor for cardiovascular
disease. Additionally, hypertension has been shown to be
associated with a greater risk of coronary allograft vascul-
opathy after OHT.19 Coronary allograft vasculopathy, in
turn, is a significant cause of both short- and long-termmor-
tality after OHT.10
Diabetes Mellitus
Diabetes mellitus has been considered a relative contrain-
dication to OHT in some centers because of the potentially
worse outcomes and worsening of diabetes resulting from
steroid immunosuppressive therapy. Previous studies have
demonstrated that patients with diabetes undergoing OHTery c February 2012
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Xexperience a greater rate of infection, rejection, and/or
transplant coronary artery disease compared with those
without diabetes.20,21 It is no surprise, therefore, that
diabetes was adversely associated with survival in the
present study. Nondiabetic elderly recipients are not
entirely spared, however, because increasing age has been
shown to be a significant risk factor for the development
of new-onset diabetes after OHT.22 Whether survival differ-
ences exist between OHT patients with pretransplant
diabetes versus recipients in whom diabetes develops in
the post-transplant period remains to be studied.
Mechanical Ventilation Before Transplantation
Mechanical ventilation before transplantation was also
associated with a reduced likelihood of 5-year survival.
This factor is likely a reflection of the acuity of transplant
and the cardiopulmonary reserve of the recipient. Addition-
ally, requiring mechanical ventilation likely translates to an
intensive care unit stay, which itself has adverse effects sec-
ondary to factors such as nutritional depletion and nosoco-
mial infection, among others. In addition, respiratory failure
requiring preoperative ventilation is a risk factor for pro-
longed ventilation postoperatively. In a study of more
than 800 patients, prolonged mechanical ventilation was as-
sociated with a greater risk of long-term mortality, particu-
larly in the elderly and those with poor prehospital
functional status.23
VAD Therapy
VAD therapy as a bridge-to-transplantationwas a variable
that was not routinely collected until the latter part of our
study period; therefore, we had a high proportion of missing
data. Although excluded from the final model, VADs were
found to be a significant independent predictor of decreased
survival on multivariate analysis incorporating other signif-
icant univariate predictors. The effect of VAD therapy on
post-transplant outcomes remains controversial, because
some centers with significant experience have demonstrated
excellent outcomes in this patient cohort and some registry
data have demonstrated an adverse effect of VAD bridging
on survival after OHT.24,25 The effect of VADs on the post-
OHT outcomes in the elderly remains an area of future
investigation.
Study Limitations
The present study had several limitations. A principal
limitation was the potential reporting biases that could be
present because UNOS is a multi-institutional database.
Additionally, as with other large national data sets, report-
ing is not complete in some instances; therefore, some vari-
ables have missing data. Other variables such as VAD
therapy were missing for most patients because that vari-
able was not being routinely collected during the study pe-
riod. Finally, other potentially predictive variables were notThe Journal of Thoracic and Caincluded in the present analysis, including surgeon volume,
center volume, other comorbidities, and preservation
methods of the donor organ, including solution used and ap-
plication method.CONCLUSIONS
As the population ages, the number of elderly patients
considered for and undergoing OHT will undoubtedly
increase. The present study analyzed multiple recipient, do-
nor, and transplant data to identify the predictors of 5-year
survival in patients older than 60 years. In the present large
cohort of more than 5000 elderly patients, younger recipient
age, white race, lower creatinine level, younger donor age,
and shorter ischemic time were found to improve 5-year
survival. Mechanical ventilation, hypertension, and diabe-
tes decreased the likelihood of 5-year survival. Bridging
with VADs, although not included in the final model be-
cause of missing data, was also found to decrease the
odds of survival, independent of the other significant cova-
riates. These data have provided a comprehensive analysis
of the factors associated with 5-year survival in elderly
OHT recipients and should serve as a useful guide in prog-
nostication in this higher risk patient cohort.References
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